The Centers for Medicare & Medicaid Services has set the Part D specialty-tier cost threshold at $1,080 a month for 2027, a 13.7 percent rise from the $950 figure standing since 2024. The number is not a benefit amount beneficiaries collect; it is the bar a drug’s monthly ingredient cost must clear before a Part D plan may place it on its costliest tier, where coinsurance can reach a third of the price. CMS last moved that bar three years ago; its 2025 and 2026 reviews found qualifying drug costs above $950 but short of the 10 percent swing needed to trigger a change, one 2027 finally cleared.
How CMS Draws the Specialty-Tier Line
Federal rule governs the mechanics behind the number rather than leaving it to each insurer’s discretion. Under 42 CFR § 423.104(d)(2)(iv), a Part D plan may place a covered drug on a specialty tier only once that drug’s 30-day equivalent ingredient cost exceeds a threshold CMS reviews once a year. CMS does not adjust the figure automatically with inflation or on a sponsor’s request. Instead, the agency recalculates the lowest ingredient cost sitting inside the top 1 percent of every 30-day equivalent cost recorded in its prescription drug event data, then measures that recalculated figure against the threshold already in force.
That test is why the number held still for two straight bidding cycles. CMS’s own analyses for plan years 2025 and 2026 each found the qualifying ingredient-cost figure running above $950, yet neither result cleared the 10 percent gap the rule requires before an adjustment is allowed, so the threshold carried over unchanged both years. The CY2027 Final Part D Bidding Instructions confirm the last increase before this one took effect for plan year 2024, meaning sponsors built three consecutive bid cycles around the same $950 cutoff while the underlying cost of high-priced drugs kept climbing.
The bidding memo itself is not a proposal open for public comment; it is a final instruction CMS sent directly to every Prescription Drug Plan, Medicare Advantage-Prescription Drug Plan, Section 1876 Cost Plan and PACE organization now assembling 2027 bids. That makes it a narrower document than the broader Contract Year 2027 Medicare Advantage and Part D policy rule, which was still open for public comment through late January 2026 when the finalized bidding instructions went out in February. The specialty-tier threshold, unlike the pieces still moving through that rulemaking, is already locked in for the bids sponsors are filing now.
Inside the kit: 51 state Medicare cost-help packs, the new Part D out-of-pocket cap, the prior-authorization appeal steps and a medication and cost tracker. Open The Medicare Cost & Coverage Protection Kit.
Why a Higher Bar Means Fewer Drugs Qualify
The mechanism sitting underneath the headline number is arithmetic rather than a policy softening. A drug reaches a specialty tier only once its monthly ingredient cost climbs above the threshold, so moving that bar from $950 to $1,080 disqualifies some drugs that used to clear it. A medication priced at roughly $1,000 a month, for instance, would have cleared specialty placement under the old cutoff and no longer clears the new one, which means a plan can no longer assign it the coinsurance rate reserved for its costliest tier.
That effect runs in a single direction. The number of drugs whose ingredient cost exceeds $1,080 is necessarily smaller than the number that used to exceed $950, so the 2027 change narrows how many drugs can carry specialty-tier cost sharing rather than expanding the category. A drug pushed below the new line is not cheaper for the plan or the manufacturer; it is simply reassigned to whatever lower-numbered tier the plan’s benefit design applies, with that tier’s ordinary copay or coinsurance schedule taking the place of the specialty rate.
The recalculation sits inside a wider overhaul of the Part D benefit tied to the Inflation Reduction Act, which eliminated the initial coverage limit that used to separate a plan’s initial coverage phase from the coverage gap starting January 1, 2025. CMS says that change made its earlier formula for capping specialty-tier cost sharing legally unworkable, so it built a replacement methodology in the Final CY2026 Part D Redesign Program Instructions and is carrying that same approach into plan year 2027 while the broader CY2027 rule remains unfinished.
What a Specialty Tier Costs Once a Drug Lands There
Crossing the threshold changes what a plan is permitted to charge, not only where a drug sits on a formulary list. Federal rule caps the coinsurance a plan may assign to a single specialty tier, or to the higher-cost specialty tier on a plan that runs two, at 25 percent for a plan that requires its standard deductible and 33 percent for a plan that waives the deductible, with intermediate percentages allowed for plans that charge a reduced deductible instead.
A plan running two specialty tiers must price its preferred specialty tier below whatever percentage applies to the higher-cost tier, giving sponsors some room to differentiate between costlier specialty drugs, though neither tier may exceed the ceiling CMS set for the year. Placement on a specialty tier also removes a drug from a plan’s ordinary tiering-exceptions process, so a beneficiary generally cannot ask a plan to reclassify a specialty medication onto a lower, less expensive tier the way exceptions work for other formulary placements.
CMS’s Medicare Drug Benefit and C&D Data Group, led by Director Vanessa S. Duran, finalized the new figure inside a February 6, 2026 memorandum that also opens the CY2027 formulary submission window on May 11, 2026 and sets a June 1, 2026 bid-filing deadline. Sponsors are now building their 2027 plan bids and drug formularies against a specialty-tier line that sits $130 higher than the cutoff they used for the last three plan years combined.
The dollar figure itself, not any accompanying marketing language, is what CMS instructs plans to apply for 2027: a 30-day equivalent ingredient cost above $1,080 clears a drug for specialty-tier placement, and a cost at or below that line does not, regardless of how a plan’s benefit summary characterizes the medication once open enrollment materials go out later this year.
Where a Drug Lands on a Tier
Nothing in the bidding memo tells an individual Medicare enrollee which of their own prescriptions sits near the new specialty-tier line, or what coinsurance a specific plan will actually charge once 2027 formularies post. That gap between the federal threshold and a person’s own drug list typically only becomes visible at the pharmacy counter, after a plan’s formulary has already been finalized for the year.
The Medicare Cost & Coverage Protection Kit is a 10-page kit with a medication and cost tracker.
Look up The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
